Online inquiry

IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5999MR)

This product GTTS-WQ5999MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ITGAV&ITGB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001144999.3; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685; 3690
UniProt ID P06756; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5999MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ528MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ3739MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ570MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ4628MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ15749MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ15018MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ8101MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ13427MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRO95780
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW